Despite the lack of national prevalence data, the prevailing expert opinion is that between 3% and 5% of US children have the disorder9"0" 9'20 and that fewer than 3% of school-aged children receive medication for ADHD.2' Prevalence studies have consistently reported ADHD to be at least 2 times more prevalent among boys than among girls.3 Similarly, ADHD studies have consistently found a positive association between ADHD and academic problems22; however, the degree of comorbidity varied greatly (from 10% to 90%) across studies. ADHD has been described as more prevalent among children from minority and low-income populations,20 but research findings challenge 23 this assumption.
vary as a function of study design, sample size, and year. The most conservative estimates (1% to 5%) have occurred in population-based studies of students with documented ADHD diagnoses9' 16; the highest estimates (16% to 26%) have occurred in studies involving smaller sample sizes and participants who meet ADHD screening criteria rather than students known to have been diagnosed with ADHD.8 '11 Despite the lack of national prevalence data, the prevailing expert opinion is that between 3% and 5% of US children have the disorder9"0" 9'20 and that fewer than 3% of school-aged children receive medication for ADHD.2' Prevalence studies have consistently reported ADHD to be at least 2 times more prevalent among boys than among girls.3 Similarly, ADHD studies have consistently found a positive association between ADHD and academic problems22; however, the degree of comorbidity varied greatly (from 10% to 90%) across studies. ADHD has been described as more prevalent among children from minority and low-income populations,20 but research findings challenge 23 this assumption. Additional studies involving data from states with low and high rates of methyl-overdiagnosis and overtreatment. In 1995, Virginia had the highest per capita methylphenidate distribution rate in the United States28; however, individual-level data were not available for epidemiologic study. The present study was designed to assess the proportion of students receiving medication for ADHD during the 1995-1996 school year in 2 school districts in southeastern Virginia. We also examined the association between ADHD medication use and students' ethnicity, sex, educational characteristics, and other social characteristics.
Methods

Study Population
The study population included all public school students enrolled in grades 2 through 5 in city A (n = 5767) and city B (n = 23 967) as of October 1, 1995 Fewer than 100 discrepancies were found, and they reflected changes that occurred between December and March.
In city B, for every student to whom ADHD medication was administered, the school nurse recorded the student's name, identification number, and medication administered as indicated by physician-signed medication administration forms. These data were collected during April 1996. A database containing this information was created and merged by name and identification number with the school district's comprehensive enrolled-student database. A subset of this database, including each student's age, race, sex, ADHD diagnosis (present or absent), and medication administered, was provided to the principal investigator. Subsequently, military family status and neighborhood codes corresponding to stuent addresses were provided for all children eligible for enrollment in city B public schools (the eligible-student data set, n = 25 924) during the 1995-1996 school year; military status and neighborhood codes were not provided for students actually enrolled as of October 1, 1995 (the enrolled-student data set, n = 23 967).
As a result of information system and personnel constraints in the school district and the lack of unique identifiers in the data sets released to the principal investigator, the eligible-student data set could not be corrected to exclude nonenrolled students, for whom ADHD information was not collected. Thus, the enrolled-student data set, rather than the eligible-student data set, was used for city B except for analysis of ADHD prevalence rates of civilian vs military families or analyses involving information associated with students' residential neighborhood.
To ensure that analysis of the eligible-student data set would yield meaningful results, we compared ADHD prevalence rates from the eligible-student and enrolled-student data sets. Rates were reduced by only 0.2% to 1.1% in race and sex categories when students who were eligible but not enrolled were included. In city A, old-for-grade students were 1.6 times as likely (P<.001) as other students to receive ADHD medication in school. In city B, age for grade was the strongest predictor of ADHD medication use. Compared with other students, students who were young for their grade were 21 times as likely to take ADHD medication (P<. 001).
In city A, use ofADHD medication was associated with median household income; however, there was a significant interaction between median household income and race (odds ratio [OR] Median household income data for city B students and public assistance data for students in both cities were significant in some analyses; however, the results varied considerably, depending on the cutpoints used to define categorical variables. Therefore, significant associations between public assistance and ADHD medication use were judged to be unreliable and are not reported.
Discussion
Our study indicates that 8% to 10% of students in grades 2 through 5 in 2 cities in Virginia received medication for ADHD during the 1995-1996 school year. These figures constitute a conservative estimate of the prevalence ofADHD among young children in the cities studied, as we accounted only for children who took medication at school. Because some children diagnosed with ADHD do not take medication at school, it is difficult to know the extent to which our data reflect the total number ofchildren diagnosed with ADHD. One study indicated that 79% of students with the disorder received at least one dose oftheir medication in school.25 AnADHD expert, Russell Barkley, estimated that 3% of US schoolchildren take medication for ADHD, while as many as 7% of US children may have the disorder.30 If this estimated ratio of children treated in school to actual cases is accurate, the true proportion of children with ADHD in eastern Vginia may be 2 to 3 times as high as the 8% to 10% we estimated.
The percentages of students receiving ADHD drug therapy were similar in the 2 cities studied, with one important exception. In cityA, old-for-grade students were more likely than other students to take ADHD medication at school. Old-for-grade students are likely to have a history of delayed school entry owing to slower development or grade retention because of poor performance. In contrast, in city B, young-for-grade students were more likely than other studets to take ADHD medication at school, with nearly two thirds of the young-for-grade students having been administered ADHD medication at school. This dramatic pevalence figure suggests the possibility that parents and professionals in city B may have misconceptions about the behavior of young children, which may have contributed to an extremely high percentage ofyoung-forgrade children receiving psychotropic medication. Follow-up studies are needed to address issues such as professionals' appreciation of developmentally appropriate inattention, impulsivity, and hyperactivity; the district's school readiness policies; and use of medication to enhance performance of precocious or academically advanced students.
Consistent with previous reports, we found that boys were more likely than girls to receive medication for ADHD. We also found that the prevalence of ADHD drug therapy increased with years in elementary school and peaked in fifth grade, by which time 18% to 20% ofWhite boys tookADHD medication at school. As was reported in a study of psychopathology among military and civilian children,3' we found that military children were more likely than civilian children to be diagnosed with ADHD. However, the magnitude of the difference was small, and it did not account for the overall high prevalence ofADHD drug therapy.
Like other developmental, learning, and mental health disorders, ADHD has been reported to be more prevalent among children from minority and low-SES environments.20 Even after controlling for factors such as median household income and sex, we found that ADHD medication was administered twice as often to Whites as to minority students. Similar racial differences were described in a recent analysis of 1991 Maryland Medicaid data.2 It is possible thatADHD is more prevalent in low-SES and minority populations than in higher-SES and nonminority populations, and that the observed differences reflect parents' decisions to fill prescriptions and/or to make prescribed medication available to their children in school. ADHD should take into account Prozac and other medications that are increasingly used to treat children diagnosed withADHD. There are some limitations to the present study. First, clinicians may have used a diagnosis ofADHD to describe children with behavioral symptoms associated with other disorders, such as depression, anxiety, learning disabilities, or child abuse. Describing such children as having ADHD may do them a disservice by depriving them of in-depth evaluations and etiologically based interventions that include requisite nonpharmacologic interventions. Inappropriate application of the diagnosis also undermines the legitimacy of the disorder for children with substantiated neurologic problems.35 The tendency to assume a biological cause for difficult child behavior, without adequately examining potential environmental contributions, has been observed in the related field of child temperament.3637 Second, there was some evidence suggesting significant associations between neighborhood factors (e.g., median household income and percentage of adults on public assistance) and ADHD medication use. However, these neighborhood (i.e., ecologic) data should be interpreted cautiously. Characterization of SES by census tract of residence does not necessarily reflect the SES of a child's family.
Despite these limitations, several important conclusions can be drawn from this population-based study. The high prevalence rates suggest that ADHD was overdiagnosed and overtreated in some groups ofchildren. On the basis of studies published through 1997, the American Medical Association's Council on Scientific Affairs concluded that "there is little evidence of widespread overdiagnosis or misdiagnosis ofADHD or widespread overprescription of methylphenidate."38(pII 00) We describe new findings that suggest regional variability in the extent ofADHD labeling and treatment. Additional prevalence studies are needed before public and professional concem about ADHD overdiagnosis and overtreatment can be dismissed. An assessment ofADHD diagnosis and methylphenidate use in regions characterized by widely differing methylphenidate distribution rates, or a national study of ADHD diagnoses and methylphenidate use, would provide information necessary to adequately address the ongoing debate about ADHD overtreatment and overdiagnosis.
In an article published in the New England Journal ofMedicine in 1975,39 Sroufe and Stewart noted that the use of methylphenidate to treat childhood behavior problems had been increasing steadily. They advocated a critical appraisal of stimulant medications before the use of such drugs increased any further. Since that article was published, hundreds of studies have documented the short-term benefits of stimulant medications, but there remains a dearth of evidence demonstrating long-term benefits of stimulant treatment on school achievement, peer relationships, or behavior problems in adolescents.40 Because of the paucity of data on the long-term consequences of stimulant medication and the unexplained racial and socioeconomic differences in ADHD treatment, the steady rise in the use of ADHD medication is an important public health issue. Further research is needed to clarify the long-term social, psychological, and biological consequences of ADHD drug therapy; to determine the prevalence of multimodal ADHD treatment; and to provide a franework for design and implementation of educational programs that ensure appropriate use of stimulant medications and nonpharmacologic interventions. K] Contributors G. B. LeFever planned the study, analyzed the data, and wrote the manuscript. K. V Dawson assisted in the logistics of accessing school division data and in data entry, data interpretation, and manuscript editing. A. L. Morrow provided guidance on all phases of the project.
